Search for content, post, videos

SynAct Pharma completes patient recruitment for Phase 2b study

SynAct Pharma has completed patient recruitment to the company’s clinical trial EXPAND which is evaluating its lead candidate compound AP1189 in early Rheumatoid Arthritis (RA) patients with severe disease activity. With all patients included into the study, dosing will be concluded in July and
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.